Leap Therapeutics Announces Strong Topline DKN-01 Combo Study Data (MCUR)
Tweet Send to a Friend
Leap Therapeutics, Inc. announced the presentation of top-line data from its clinical trial of DKN-01 combination therapy in patients with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
